Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that target… Read more
Dianthus Therapeutics Inc. - Asset Resilience Ratio
Dianthus Therapeutics Inc. (DNTH) has an Asset Resilience Ratio of 66.53% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Dianthus Therapeutics Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Dianthus Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $353.21 Million | 66.53% |
| Total Liquid Assets | $353.21 Million | 66.53% |
Asset Resilience Insights
- Very High Liquidity: Dianthus Therapeutics Inc. maintains exceptional liquid asset reserves at 66.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Dianthus Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Dianthus Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Dianthus Therapeutics Inc. (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Dianthus Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 66.53% | $353.21 Million | $530.92 Million | -0.97pp |
| 2024-12-31 | 67.50% | $252.45 Million | $374.01 Million | +44.43pp |
| 2023-12-31 | 23.07% | $41.39 Million | $179.41 Million | -49.27pp |
| 2022-12-31 | 72.34% | $60.12 Million | $83.11 Million | +48.51pp |
| 2021-12-31 | 23.84% | $45.28 Million | $189.93 Million | -32.27pp |
| 2020-12-31 | 56.11% | $90.68 Million | $161.62 Million | +6.17pp |
| 2019-12-31 | 49.94% | $80.66 Million | $161.51 Million | -3.60pp |
| 2018-12-31 | 53.54% | $84.22 Million | $157.31 Million | -- |